Inflammation, apoptosis, and BPH: What is the evidence?

European Urology, Supplements

Volumn 5, Issue 4 SPEC. ISS., 2006, Pages 401-409

  Novara, Giacomo ^a   Galfano, Antonio ^a   Berto, Rafael Boscolo ^a   Ficarra, Vincenzo ^b   Navarrete, Remigio Vela ^c   Artibani, Walter ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

5 Reductase; Apoptosis; Benign prostate hyperplasia; Caspase; Doxazosin; Dutasteride; Finasteride; Inflammation; Inhibitors; Phytotherapeutic agents; Serenoa repens; Terazosin; Blockers

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; DOXAZOSIN; DUTASTERIDE; FATTY ACID; FINASTERIDE; INTERLEUKIN 17; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOXYBENZAMINE; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

APOPTOSIS; CELL REGENERATION; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; EFFECTOR CELL; HUMAN; INFLAMMATION; INFLAMMATORY CELL; META ANALYSIS; NONHUMAN; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TISSUE INJURY; URINARY TRACT INFECTION;

EID: 33644787123     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.02.003     Document Type: Article

References (60)

1. S. Madersbacher, G. Alivizatos, J. Nordling, C.R. Sanz, M. Emberton, and J.J. de la Rosette EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines) Eur Urol 46 2004 547 554
2. J.J. Barry, D.S. Coffey, P.C. Walsh, and L.L. Ewing The development of human benign prostatic hyperplasia with age J Urol 132 1984 474 479
3. D.G. Bostwick, W.H. Cooner, L. Denis, G.W. Jones, P.T. Scardino, and G.P. Murphy The association of benign prostatic hyperplasia and cancer of the prostate Cancer 70 1992 291 301
4. J. McNeal Pathology of benign prostatic hyperplasia. Insight into etiology Urol Clin North Am 17 1990 477 486
5. H.M. Arrighi, E.J. Metter, H.A. Guess, and J.L. Fozzard Natural history of benign prostatic hyperplasia and risk of prostatectomy, the Baltimore Longitudinal Study of Aging Urology 35 1991 4 8
6. C.G. Chute, L.A. Panser, and C.J. Girman The prevalence of prostatism: a population based survey of urinary symptoms J Urol 150 1993 85 89
7. P.M. Henson Dampening inflammation Nat Immunol 6 2005 1179 1181
8. A. Degterev, M. Boyce, and J. Yuan A decade of caspases Oncogene 22 2003 8543 8567
9. N. Konno-Takahashi, T. Takeuchi, and H. Nishimatsu Engineered FGF-2 expression induces glandular epithelial hyperplasia in the murine prostatic dorsal lobe Eur Urol 46 2004 126 132
10. C. Lee, A. Cockett, O. Cussenot, K. Griffiths, W. Isaacs, and J. Schalken Regulation of prostate growth C. Chatelain L. Denis J.K.T. Foo Fifth International Consultation on Benign Prostatic Hyperplasia 2001 Health Publications Plymouth, United Kingdom 81 106
11. K.L. Lee, and D.M. Peehl Molecular and cellular pathogenesis of benign prostatic hyperplasia J Urol 172 2004 1784 1791
12. G.J.L.H. van Leenders, W.R. Gage, and J.L. Hicks Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy Am J Pathol 162 2003 1529 1537
13. N. Kyprianou Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance J Urol 169 2003 1520 1525
14. M. Marcelli, T.C. Shao, and X.I. Li Induction of apoptosis in BPH stromal cells by adenoviral-mediated overexpression of caspase-7 J Urol 164 2000 518 525
15. S.F. Shariat, R. Ashfaq, C.G. Roehrborn, K.M. Slawin, and Y. Lotan Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia J Urol 174 2005 2046 2050
16. G. Untergasser, S. Madersbacher, and P. Berger Benign prostatic hyperplasia: age-related tissue-remodeling Exp Gerontol 40 2005 121 128
17. P.H. Schatteman, L. Hoekx, J.J. Wyndaele, W. Jeuris, and E. Van Marck Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density Eur Urol 37 2000 404 412
18. Y. Kakehi, T. Segawa, and X.X. Wu Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia Prostate 59 2004 351 356
19. G.E. Steiner, M.E. Newman, and D. Paikl Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate Prostate 56 2003 171 182
20. P. Castro, C. Xia, and L. Gomez Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia Prostate 60 2004 153 159
21. P. Castro, D. Giri, D. Lamb, and M. Ittmann Cellular senescence in the pathogenesis of benign prostatic hyperplasia Prostate 55 2003 30 38
22. W. Wang, A. Bergh, and J.E. Damber Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium Prostate 61 2004 60 72
23. F. Di Silverio, V. Gentile, and A. De Matteis Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis Eur Urol 23 2003 164 175
24. Roehrborn CG, Kaplan SA, Noble WS, et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study. AUA meeting 2005. J Urol 2005; 173 (Suppl 4): 346 (abstract 1277).
25. S. Rohrmann, A.M. De Marzo, and E. Smit Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III) Prostate 62 2005 27 33
26. N. Kyprianou, H. Tu, and S.C. Jacobs Apoptotic versus proliferative activities in human benign prostatic hyperplasia Hum Pathol 27 1996 668 675
27. M. Colombel, F. Vacherot, S.G. Diez, E. Fontaine, R. Buttyan, and D. Chopin Zonal variation of apoptosis and proliferation in the normal prostate and in benign prostatic hyperplasia Br J Urol 82 1998 380 385
28. S. Claus, R. Berges, T. Senge, and H. Schulze Cell kinetic in epithelium and stroma of benign prostatic hyperplasia J Urol 158 1997 217 221
29. S. Tunn, R. Nass, A. Ekkernkamp, H. Schulze, and M. Krieg Evaluation of average life span of epithelial and stromal cells of human prostate by superoxide dismutase activity Prostate 15 1989 263 271
30. J. Choi, I. Shendrik, and M. Peacocke Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia Urology 56 2000 160 166
31. N. Kyprianou, J.P. Litvak, A. Borkowski, R. Alexander, and S.C. Jacobs Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia J Urol 159 1998 1810 1815
32. J.K. Chon, A. Borkowski, A.W. Partin, J.T. Isaacs, S.C. Jacobs, and N. Kyprianou Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia J Urol 161 1999 2002 2008
33. A. Tahmatzopoulos, and N. Kyprianou Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality? Prostate 59 2004 91 100
34. D.T. Glassman, J.K. Chon, A. Borkowski, S.C. Jacobs, and N. Kyprianou Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia Prostate 46 2001 45 51
35. K.Y. Ilio, I.I. Park, M.R. Pins, J.M. Kozlowski, and C. Lee1 Apoptotic activity of doxazosin on prostate stroma in vitro is mediated through an autocrine expression of TGF-b1 Prostate 48 2001 131 135
36. C.M. Benning, and N. Kyprianou Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor- independent action Cancer Res 62 2002 597 602
37. R.S. Rittmaster, R.W. Norman, L.N. Thomas, and G. Rowden Evidence for atrophy and apoptosis in the prostates of men given finasteride J Clin Endocrinol Metab 81 1996 814 819
38. H. Huynh, R.M. Seyam, and G.B. Brock Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I), IGF-I receptor and an increase in IGF binding protein 3 Cancer Res 58 1998 215 218
39. H. Huynh Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins Int J Oncol 20 2002 1297 1303
40. C. Saez, A.C. Gonzalez-Baena, and M.A. Japon Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGF-b receptor expression Prostate 37 1998 84 90
41. A. Bozec, A. Ruffion, and M. Decaussin Activation of caspases-3, -6, and -9 during finasteride treatment of benign prostatic hyperplasia J Clin Endocrinol Metab 80 2005 17 25
42. L.J. Schmidt, H. Murillo, and D.J. Tindall Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride J Androl 25 2004 944 953
43. G.L. Andriole, P. Humphrey, and P. Ray Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer J Urol 172 2004 915 919
44. C.B. Lazier, L.N. Thomas, R.C. Douglas, J.P. Vessey, and R.S. Rittmaster Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line Prostate 58 2004 130 144
45. J.D. McConnell, C.G. Roehrborn, and O.M. Bautista The long-term effect of doxazosin, finasteride, and combination therapy on the progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387 2398
46. T.J. Wilt, A. Ishani, I. Rutks, and R. MacDonald Phytotherapy for benign prostatic hyperplasia Public Health Nutr 3 2000 459 472
47. P. Boyle, C. Robertson, F. Lowe, and C. Roehrborn Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia BJU Int 93 2004 751 756
48. A.C. Buck Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? Mechanisms of action J Urol 172 2004 1792 1799
49. R. Vela-Navarrete, J.V. Garcia Cardoso, A. Barat, F. Manzarbeitia, and A. Lopez Farre BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay Eur Urol 44 2003 549 555
50. F. Vacherot, M. Azzouz, and S. Gil-Diez-De-Medina Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon) in benign prostatic hyperplasia Prostate 45 2000 259 266
51. R. Vela-Navarrete, M. Escribano-Burgos, A.L. Farre, J. Garcia-Cardoso, F. Manzarbeitia, and C. Carrasco Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia J Urol 173 2005 507 510
52. W.G. Nelson, A.M. De Marzo, and W.B. Isaacs Prostate cancer N Engl J Med 349 2003 366 381
53. G.S. Palapattu, S. Sutcliffe, and P.J. Bastian Prostate carcinogenesis and inflammation: emerging insights Carcinogenesis 26 2005 1170 1181
54. A.M. De Marzo, T.L. DeWeese, and E.A. Platz Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment J Cell Biochem 91 2004 459 477
55. S. Gupta, V.M. Adhami, and M. Subbarayan Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model Cancer Res 64 2004 3334 3343
56. E.J. Jacobs, C. Rodriguez, and A.M. Mondul A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence J Natl Cancer Inst 97 2005 975 980
57. E.A. Platz, S. Rohrmann, and J.D. Pearson Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging Cancer Epidemiol Biomarkers Prev 14 2005 390 396
58. D.S. Dandekar, M. Lopez, R.I. Carey, and B.L. Lokeshwar Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells Int J Cancer 115 2005 484 492
59. L. Zeng, R.G. Rowland, S.M. Lele, and N. Kyprianou Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate Hum Pathol 35 2004 290 297
60. M. Ricote, M. Royuela, I. Garcia-Tunon, F.R. Bethencourt, R. Paniagua, and B. Fraile Pro-apoptotic tumor necrosis factor-alpha transduction pathway in normal prostate, benign prostatic hyperplasia and prostatic carcinoma J Urol 170 2003 787 790